Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 10/20 | 0.82 |
| ▸ | PTPN2 | P17706 | 6/20 | 0.82 |
| ▸ | ACP1 | P24666 | 2/20 | 0.82 |
| ▸ | USP2 | O75604 | 1/20 | 0.69 |
| ▸ | CETP | P11597 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637482 | 1.00 | PTPN1 (0.82) | PTPN1PTPN2ACP1USP2CETP | |
| SCHEMBL29485172 | 0.94 | PTPN1 (0.79) | PTPN1PTPN2ACP1USP2CETP | |
| SCHEMBL22335213 | 0.90 | PTPN1 (1.00) | PTPN1PTPN2ACP1USP2CETP | |
| SCHEMBL31237492 | 0.89 | PLCG1 (0.78) | PTPN1PTPN2ACP1USP2CETP | |
| SCHEMBL3952674 | 0.87 | POLB (0.70) | PTPN1PTPN2ACP1USP2CETP | |
| SCHEMBL31510833 | 0.83 | PTPN1 (0.74) | PTPN1PTPN2ACP1USP2 | |
| SCHEMBL22454233 | 0.83 | PTPN1 (0.56) | PTPN1PTPN2ACP1USP2 | |
| SCHEMBL19410623 | 0.83 | PTPN1 (0.56) | PTPN1PTPN2ACP1USP2 | |
| Acetyl Oleanolic Acid SCHEMBL23284080 | 0.82 | PTPN1 (1.00) | PTPN1PTPN2ACP1USP2CETP | |
| Acetyl Oleanolic Acid SCHEMBL21703054 | 0.82 | PTPN1 (1.00) | PTPN1PTPN2ACP1USP2CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012795-A4 | THERAPEUTIC TRITERPENOIDS | UNIV MINNESOTA (US) | 2009-07-22 | — | — | EP | claimed |
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-05-28 | — | — | US | claimed |
| EP-2012795-A2 | THERAPEUTIC TRITERPENOIDS | Regents of the University of Minnesota (US) | 2009-01-14 | — | — | EP | claimed |
| WO-2007121352-A2 | THERAPEUTIC TRITERPENOIDS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2007-10-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136566-A1 | THERAPEUTIC TRITERPENOIDS | EBP, PGGT1B, LIPC | PTPN1 3600/4885PTPN2 2899/4885ACP1 3379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.